Recently, the results of two Phase III clinical studies (DREAMS-1 and DREAMS-2) of mazdutide in Chinese patients with type 2 diabetes mellitus (T2DM) have been jointly published in the prestigious journal Nature.
Following presentations at the Scientific Sessions of the American Diabetes Association (ADA) and the Annual Meeting of the European Association for the Study of Diabetes (EASD) earlier this year, the dual studies have now appeared together in one of the world’s top academic journals, achieving several historic milestones:
This marks the first time that Nature has published back-to-back Phase III clinical studies in the field of metabolic and endocrine diseases.
Mazdutide becomes the first drug in the history of China’s pharmaceutical industry to have two clinical studies published simultaneously in Nature.Notably, in May this year, mazdutide’s weight management series was published in The New England Journal of Medicine (NEJM).It is now the only GLP‑1 receptor agonist to have been featured in both Nature and NEJM.
This represents not only a remarkable academic achievement but also a milestone for China’s diabetes research after years of dedicated effort.To decode the core advantages of the dual‑receptor agonist’s innovative mechanism and its clinical value, Professor Guo Lixin from Beijing Hospital — Principal Investigator and first author of the DREAMS‑2 study — provided an in-depth professional interpretation.
In an interview, Professor Guo Lixin stated:“The breakthrough of the DREAMS‑1 and DREAMS‑2 studies lies in their use of high-quality clinical data from the Chinese population to validate, for the first time, the mechanistic advantages and clinical value of the glucagon (GCG)/glucagon-like peptide‑1 (GLP‑1) dual-receptor agonist administered weekly in diabetes treatment.They fill a global gap in metabolic research by providing both ‘Chinese data’ and evidence for the ‘innovative GCG/GLP‑1 dual-receptor mechanism’ — key reasons for their acceptance by top academic journals.”
Compared with traditional single GLP‑1 receptor agonists, mazdutide offers unique benefits:
It activates the GLP‑1 receptor to promote insulin secretion, lower blood glucose, and reduce body weight.
It also activates the GCG receptor to increase energy expenditure, enhance weight loss, and improve fat metabolism.Together, these actions deliver multiple benefits: glycemic control, weight reduction, and improved metabolic health.
The publication of the two Phase III studies in Nature confirms mazdutide’s superior efficacy in both glucose lowering and weight management.In addition, both studies showed clinically meaningful and significant improvements in waist circumference, blood pressure, blood lipids, liver enzymes, and other metabolic parameters, demonstrating the unique advantages of the GCG target.
As a China-invented dual-receptor agonist, mazdutide combines an innovative mechanism with data specific to Chinese patients, precisely addressing the core clinical need for comprehensive metabolic management.
Compared with traditional single-target drugs, mazdutide achieves broad, integrated metabolic benefits through dual-receptor synergy:
In overweight or obese patients with baseline liver fat content ≥ 10%, mazdutide 6 mg reduced total liver fat content by 80.2% after 48 weeks of treatment, offering a highly effective option for patients with metabolic dysfunction-associated steatotic liver disease.
The GLORY‑1 study showed that mazdutide reduced systolic blood pressure by an average of 9.21 mmHg, providing dual benefits for obese patients with hypertension.
It also simultaneously lowered serum uric acid and triglyceride levels, achieving synergistic improvements across multiple metabolic markers.The metabolic benefits of mazdutide cover multiple key cardiometabolic risk factors, directly addressing the clinical challenge of T2DM patients often presenting with multiple comorbidities.